Therefore, this conceptually novel strategy might open impressive avenues to establish green and sustainable chemistry platforms. If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 179324-87-9, Quality Control of (R)-BoroLeu-(+)-Pinanediol trifluoroacetate.
New Advances in Chemical Research, April 2021.The transformation of simple hydrocarbons into more complex and valuable products via catalytic C–H bond functionalisation has revolutionised modern synthetic chemistry. 179324-87-9, Name is (R)-BoroLeu-(+)-Pinanediol trifluoroacetate, SMILES is CC1(C)[C@@]([H])(C2)C[C@]3([H])[C@](OB([C@H](CC(C)C)N)O3)(C)[C@]12[H].O=C(O)C(F)(F)F, belongs to naphthyridine compound. In a document, author is Wright, Galen E. B., introduce the new discover, Quality Control of (R)-BoroLeu-(+)-Pinanediol trifluoroacetate.
Background Huntington’s disease is a fatal neurodegenerative disorder that is caused by CAG-CAA repeat expansion, encoding polyglutamine, in the huntingtin (HTI) gene. Current age-of-clinical-onset prediction models for Huntington’s disease are based on polyglutamine length and explain only a proportion of the variability in age of onset observed between patients. These length-based assays do not interrogate the underlying genetic variation, because known genetic variants in this region do not alter the protein coding sequence. Given that individuals with identical repeat lengths can present with Huntington’s disease decades apart, the search for genetic modifiers of clinical age of onset has become an active area of research. Recent developments Results from three independent genetic studies of Huntington’s disease have shown that glutamine-encoding CAA variants that interrupt DNA CAG repeat tracts, but do not alter polyglutamnine length or polyglutamine homogeneity, are associated with substantial differences in age of onset of Huntington’s disease in carriers. A variant that results in the loss of CAA interruption is associated with early onset and is particularly relevant to individuals that carry alleles in the reduced penetrance range (ie, CAG 36-39). Approximately a third of clinically manifesting carriers of reduced penetrance alleles, defined by current diagnostics, carry this variant. Somatic repeat instability, modified by interrupted CAG tracts, is the most probable cause mediating this effect. This relationship is supported by genome-wide screens for disease modifiers, which have revealed the importance of DNA-repair genes in Huntington’s disease (ie, FAN1, LIG1, MLH1, MSH3, PMS1, and PMS2). Where next? Focus needs to be placed on refining our understanding of the effect of the loss-of-interruption and duplication-of-interruption variants and other interrupting sequence variants on age of onset, and assessing their effect in disease-relevant brain tissues, as well as in diverse population groups, such as individuals from Africa and Asia. Diagnostic tests should be augmented or updated, since current tests do not assess the underlying DNA sequence variation, especially when assessing individuals that carry alleles in the reduced penetrance range. Future studies should explore somatic repeat instability and DNA repair as new therapeutic targets to modify age of onset in Huntington’s disease and in other repeat-mediated disorders. Disease-modifying therapies could potentially be developed by therapeutically targeting these processes. Promising approaches include therapeutically targeting the expanded repeat or directly perturbing key DNA-repair genes (eg, with antisense oligonucleotides or small molecules). Targeting the CAG repeat directly with naphthyridine-azaquinolone, a compound that induces contractions, and altering the expression of MSH3, represent two viable therapeutic strategies. However, as a first step, the capability of such novel therapeutic approaches to delay clinical onset in animal models should be assessed.
Therefore, this conceptually novel strategy might open impressive avenues to establish green and sustainable chemistry platforms. If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 179324-87-9, Quality Control of (R)-BoroLeu-(+)-Pinanediol trifluoroacetate.
Reference:
1,8-Naphthyridine – Wikipedia,
,1,8-Naphthyridine | C8H6N2 – PubChem